Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.

abstract：:Several surveys have defined chronic lymphocytic leukemia (CLL) patients as a high-risk patient population for developing second neoplasms. As possible mechanisms underlying the increased risk of specific second malignancies in CLL patients the immunodeficiency associated with disease is generally proposed. As far as ...

journal_title：Leukemia & lymphoma

authors： Molica S

更新日期：2005-01-01 00:00:00

abstract：:Interleukin-4 (IL-4), also known as B-cell stimulatory factor-1 (BSF-1), was initially identified as a T-cell product that mediates anti-IgM-induced DNA synthesis in B-lymphocytes. Various aspects of this highly pleiotropic cytokine have been described, including those on hematopoietic progenitor cells. However, the r...

journal_title：Leukemia & lymphoma

authors： Sawada K,Sato N,Koike T

更新日期：1995-09-01 00:00:00

abstract：:Bone marrow scintigraphy is a simple and noninvasive examination useful to define the status of the bone marrow and spleen in polycythaemia vera (P.V.). Despite the absence of specificity of Indium 111 labelled transferrin (In-Tf) for myelopoietic tissue, there is a close correlation between bone marrow In-Tf uptake a...

journal_title：Leukemia & lymphoma

authors： Rain JD,Najean Y,Billotey C

更新日期：1996-09-01 00:00:00

abstract：:We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the imma...

journal_title：Leukemia & lymphoma

authors： Lee JJ,Choi BH,Kang HK,Park MS,Park JS,Kim SK,Pham TN,Cho D,Nam JH,Kim YJ,Rhee JH,Yang DH,Kim YK,Kim HJ,Chung IJ

更新日期：2007-10-01 00:00:00

abstract：:We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 ...

journal_title：Leukemia & lymphoma

authors： Crocchiolo R,Canevari C,Assanelli A,Lunghi F,Tassara M,Stanghellini ML,Clerici D,Landoni C,Servida P,Bernardi M,Peccatori J,Ferreri A,Gianolli L,Bordignon C,Caligaris-Cappio F,Ciceri F,Fazio F

更新日期：2008-04-01 00:00:00

abstract：:Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). We undertook a retrospective analysis of AML patients age...

journal_title：Leukemia & lymphoma

authors： Loh YS,Koh LP,Tai BC,Hwang WY,Linn YC,Goh YT,Tan PH

更新日期：2007-01-01 00:00:00

abstract：:In this report, we present a patient with chronic myeloid leukemia (CML) in blastic phase who had two consecutive episodes of spontaneous regression back to chronic phase without chemotherapy. Although, spontaneous remission (SR) is well documented in acute leukemia, SR in CML blastic phase is extremely rare and to th...

journal_title：Leukemia & lymphoma

authors： Cağirgan S,Sencan M,Tombuloglu M,Ozdemir E,Hekimgil M,Büyükkeçeci F

更新日期：1998-04-01 00:00:00

abstract：:Chronic exposure to high concentrations of benzene is associated with an increased incidence of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving loss of all or part of chromosomes 5 and/or 7 as...

journal_title：Leukemia & lymphoma

authors： Stillman WS,Varella-Garcia M,Irons RD

更新日期：1999-10-01 00:00:00

abstract：:Multiple myeloma (MM) is an essentially incurable malignancy associated with profound immune dysregulation. Despite the advent of novel therapies and improvements in survival over the last 10 years, death from progressive disease and infection remains a common outcome. Natural killer (NK) cells are CD56(+)CD3(-) large...

journal_title：Leukemia & lymphoma

authors： Godfrey J,Benson DM Jr

更新日期：2012-09-01 00:00:00

abstract：:The natural history of the chronic phase (CP) of chronic myeloid leukemia (CML) and the high response rates achieved with BCR-ABL inhibitor therapy necessitate long-term evaluation of survival-based outcome measures. Prior to the availability of long-term BCR-ABL inhibitor data, short-term surrogate end points predict...

journal_title：Leukemia & lymphoma

authors： Akwaa F,Liesveld J

更新日期：2013-10-01 00:00:00

abstract：:The objective of this study was to assess the impact of the primary prophylaxis of granulocyte colony-stimulating factor (G-CSF) in the management of childhood B-cell non-Hodgkin lymphoma (B-NHL). Patients with advanced-stage mature B-NHL were randomized to receive prophylactic G-CSF (G-CSF+) or not receive G-CSF (G-C...

journal_title：Leukemia & lymphoma

authors： Tsurusawa M,Watanabe T,Gosho M,Mori T,Mitsui T,Sunami S,Kobayashi R,Fukano R,Tanaka F,Fujita N,Inada H,Sekimizu M,Koh K,Kosaka Y,Komada Y,Saito AM,Nakazawa A,Horibe K,lymphoma committee of the Japanese Pediatric Leuke

更新日期：2016-07-01 00:00:00

abstract：:Splenectomy specimens from 8 cases of chronic lymphocytic leukaemia (CLL) were examined. The infiltrate in the red pulp consisted predominantly of small lymphocytes. In contrast the predominant cells in the white pulp were pro-lymphocytes and para-immunoblasts. The Ki67 marker, which identifies cells in growth phase, ...

journal_title：Leukemia & lymphoma

authors： Lampert IA,Hegde U,Van Noorden S

更新日期：1990-01-01 00:00:00

abstract：:Composite lymphomas constitute the presence of two different types of non-Hodgkin lymphoma or Hodgkin and non-Hodgkin lymphoma at the same anatomic site. We report an unusual case of a 73-year-old woman who initially presented with a composite lymphoma of chronic lymphocytic leukemia (CLL) and follicular lymphoma. Aft...

journal_title：Leukemia & lymphoma

authors： Copur MS,Ledakis P,Novinski D,Fu K,Hutchins M,Frankforter S,Mleczko K,Sanger WG,Chan WC

更新日期：2004-05-01 00:00:00

abstract：:Although considered the same disease by 2016 WHO Classification, B-ALL and B-LBL show different clinicobiologic behavior, with B-ALL manifesting as disseminated disease and B-LBL as a localized mass. Distinction between the two is based on an arbitrary cutoff of 25% bone marrow involvement. We reviewed clinical, immun...

journal_title：Leukemia & lymphoma

authors： Knez V,Bao L,Carstens B,Liang X

更新日期：2020-09-01 00:00:00

abstract：:Despite maturation arrest, blast cells in acute myeloid leukemia (AML) are often capable of expressing lineage-restricted (granulomonocytic or myelomastocytic) differentiation antigens. Tryptases are lineage-associated serine proteases primarily expressed in mast cells, and less abundantly in blood basophils. We have ...

journal_title：Leukemia & lymphoma

authors： Sperr WR,Hauswirth AW,Valent P

更新日期：2002-12-01 00:00:00

abstract：:MDSCs, which are defined as a kind of negatively regulatory cells, could suppress T cell immune response in many tumor-bearing animal models and cancer patients. We supposed that MDSCs also contributed to the impaired antitumor immunity in MDS. Here we demonstrated that STAT3-ARG1 pathway could be a critical signal tr...

journal_title：Leukemia & lymphoma

authors： Qi X,Jiang H,Liu P,Xie N,Fu R,Wang H,Liu C,Zhang T,Wang H,Shao Z

更新日期：2021-01-01 00:00:00

abstract：:Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses hav...

journal_title：Leukemia & lymphoma

authors： Hagemeister FB

更新日期：1993-01-01 00:00:00

abstract：:Multiple myeloma is a genetically heterogenous disease with a wide variety of characterized genetic aberrations. Until recently, the impact of these aberrations on patient outcome was not known. However, in the last 5-10 years, several genetic markers have been linked to patient outcome. One of the strongest predictor...

journal_title：Leukemia & lymphoma

authors： Keats JJ,Reiman T,Belch AR,Pilarski LM

更新日期：2006-11-01 00:00:00

abstract：:The importance of obtaining a tumor-free graft for autologous transplantation in cancer patients has been debated extensively in the last decade and is still unresolved largely because it is believed that relapse is more likely to originate from the host and not from the graft. This is in spite of recent indications t...

journal_title：Leukemia & lymphoma

authors： Gazitt Y,Reading CL

更新日期：1996-10-01 00:00:00

abstract：:Immunomodulatory drugs (IMiDs) may favor autoimmune disease (AD) occurrence. We conducted a retrospective study to evaluate AD occurrence among IMiD-treated patients with myeloma. Patients were grouped into three classes depending on the type of IMiD engaged. The first group included patients treated with thalidomide ...

journal_title：Leukemia & lymphoma

authors： Montefusco V,Galli M,Spina F,Stefanoni P,Mussetti A,Perrone G,De Philippis C,Dalto S,Maura F,Bonini C,Rezzonico F,Pennisi M,Roncari L,Soldarini M,Dodero A,Farina L,Cocito F,Caprioli C,Corradini P

更新日期：2014-09-01 00:00:00

abstract：:A retrospective clinico-pathological study was performed on 208 consecutively recruited patients (94 males, 114 females, median age 67 years) with idiopathic (primary) osteo-/ myelofibrosis (IMF). According to bone marrow histology (cellularity) as well as extent (semiquantitative grading) and quality (reticulin/colla...

journal_title：Leukemia & lymphoma

authors： Thiele J,Kvasnicka HM,Werden C,Zankovich R,Diehl V,Fischer R

更新日期：1996-07-01 00:00:00

abstract：:The Rai and Binet staging systems, which are used as standard methods for evaluating the prognosis of chronic lymphocytic leukemia (CLL), have some restrictions in identifying patients with early-stage CLL who will progress rapidly. To solve this defect, other prognostic parameters have become important in recent year...

journal_title：Leukemia & lymphoma

authors： Hancer VS,Kose M,Diz-Kucukkaya R,Yavuz AS,Aktan M

更新日期：2011-01-01 00:00:00

abstract：:Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of lenalidomide and dexamethasone as frontline pre-transplant induction, with doses adjusted at start of each cycle based on cre...

journal_title：Leukemia & lymphoma

authors： Chen CI,Cao Y,Trudel S,Reece DE,Kukreti V,Tiedemann R,Prica A,Paul H,Le LW,Levina O,Kakar S,Lau A,Chen H,Chen E

更新日期：2020-08-01 00:00:00

abstract：:Mononuclear phagocytic cells and CD4+ T lymphocytes represent the major targets for infection by HIV-1 in vivo. The most severe pathogenic features associated with HIV-1 infection can be attributed to malfunction or premature death of these cells that are of hematopoietic origin. Patients with acquired immunodeficienc...

journal_title：Leukemia & lymphoma

authors： Kulkosky J,Bouhamdan M,Geist A,Nunnari G,Phinney DG,Pomerantz RJ

更新日期：2000-05-01 00:00:00

abstract：:The emergence of radioimmunotherapy (RIT) provides a new therapeutic approach in which monoclonal antibodies directed against tumor-specific antigens are used to target therapeutic radioisotopes to sites of disseminated disease. The target cell is eliminated and adjacent tumor cells, to which antibody has not bound, a...

journal_title：Leukemia & lymphoma

authors： Bischof Delaloye A

更新日期：2003-01-01 00:00:00

abstract：:Since unlimited proliferative potential has been identified as a major and, to date, therapeutically unexploited phenotypic hallmark of cancer, telomere maintenance mechanisms have been proposed as potential targets for new anticancer interventions. This study was aimed to investigate the effects of BIBR1532, the lead...

journal_title：Leukemia & lymphoma

authors： Bashash D,Ghaffari SH,Mirzaee R,Alimoghaddam K,Ghavamzadeh A

更新日期：2013-03-01 00:00:00

abstract：:Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by study. Sixty-nine cases of diffuse large B-cell lymphoma were evalua...

journal_title：Leukemia & lymphoma

authors： Clark Schneider KM,Banks PM,Collie AM,Lanigan CP,Manilich E,Durkin LM,Hill BT,Hsi ED

更新日期：2016-07-01 00:00:00

abstract：:A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated. ...

journal_title：Leukemia & lymphoma

authors： Bompas E,Velay B,Blay JY

更新日期：2004-11-01 00:00:00

abstract：:Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

journal_title：Leukemia & lymphoma

authors： Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

更新日期：2006-06-01 00:00:00

abstract：:A two-year-old boy presented with pancytopenia. Bone marrow examination revealed an aplastic marrow with prominent immature plasma cell proliferation, which mimicked plasma cell leukemia. Immunohistochemistry, however, revealed a polyclonal population consistent with a reactive process, excluding plasma cell neoplasia...

journal_title：Leukemia & lymphoma

authors： Kikuchi M,Ohsaka A,Chiba Y,Sato M,Muraosa Y,Hoshino H

更新日期：1999-09-01 00:00:00